Rapid Readouts

Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.

Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice.

Sandip P. Patel, MD, reviews data from the preliminary results of the EVOKE-02 study investigating sacituzumab govitecan plus pembrolizumab in first-line metastatic non–small cell lung cancer.

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

Jason R. Westin, MD, MS, FACP, presents the overall survival analysis from ZUMA-7, a phase 3 study investigating axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.

Whitney S. Graybill, MD, MS, presents data from an analysis of the phase 3 PRIMA trial that looked to identify baseline characteristics associated with long-term progression-free survival with niraparib in patients with advanced ovarian cancer.

Marcelo Negrao, MD, presents key data from the KRYSTAL-1 trial investigating adagrasib in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) and untreated central nervous system (CNS) metastases.

Jane Lowe Meisel, MD, presents data from a retrospective study investigating patient characteristics, treatment patterns, and clinical outcomes for tucatinib-based treatment in the real-world setting both overall and following fam-trastuzumab deruxtecan (T-DXd).

Alexey Danilov, MD, PhD, reviews data from the phase 2 TRANSCEND FL trial investigating lisocabtagene maraleucel and discusses the clinical implications of the results.

Marwan G. Fakih, MD, reviews data from the phase 3 randomized SUNLIGHT trial investigating trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer.

Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Matthew Powell, MD, presents data from the blinded independent central review of the RUBY trial, which studied dostarlimab in patients with primary advanced or recurrent endometrial cancer.

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.

Alexey Danilov, MD, PhD, presents an analysis of data from the Phase 1 TRANSCEND CLL 004 study investigating lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.

Paolo Ghia, MD, PhD, reviews data from the ELEVATE-RR trial investigating acalabrutinib versus ibrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

Greg Roloff, MD, reviews data on the outcomes of patients with relapsed/refractory B-ALL who received treatment with brexucabtagene autoleucel.

Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.

Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.

Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.

Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).

Guillermo Garcia-Manero, MD, reviews data from the COMMANDS trial comparing the efficacy and safety of luspatercept to epoetin alfa in patients with lower-risk myelodysplastic syndromes (MDS) who are dependent on blood transfusions and have not previously received erythropoiesis-stimulating agents (ESAs).

Expert Scott Tagawa, MD, MS, FASCO, FACP, reviews recent clinical trial data on UGT1A1- and Trop-2–guided treatment of metastatic urothelial carcinoma.

Expert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Jayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.